A. Jemal, R. Siegel, J. Xu, and E. Ward, Cancer Statistics, vol.60, issue.5, pp.277-300, 2010.

F. Binder-foucard, N. Bossard, P. Delafosse, A. Belot, A. Woronoff et al., Cancer incidence and mortality in France over the 1980-2012 period: solid tumors, Rev Epidemiol Sante Publique, vol.62, issue.2, pp.95-108, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915012

N. Mottet, J. Bellmunt, M. Bolla, E. Briers, M. G. Cumberbatch et al., EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent, Eur Urol, vol.71, issue.4, pp.618-647, 2017.

G. D. Grossfeld, D. M. Latini, D. P. Lubeck, S. S. Mehta, and P. R. Carroll, Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer, J Urol, vol.169, issue.1, pp.157-63, 2003.

L. Evangelista, F. Zattoni, A. Guttilla, G. Saladini, F. Zattoni et al., Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis, Clin Nucl Med, vol.38, issue.5, pp.305-319, 2013.

S. Kanoun, P. Walker, J. Vrigneaud, E. Depardon, V. Barbier et al., 18 F-Choline Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging for the Detection of Early Local Recurrence of Prostate Cancer Initially Treated by Radiation Therapy: Comparison With Systematic 3-Dimensional Transperineal Mapping Biopsy, Int J Radiat Oncol, vol.97, issue.5, pp.986-94, 2017.

K. Jéhannin-ligier, E. Dantony, and Z. Uhry, Projection de l'incidence et de la mortalité par cancer en France métropolitaine en 2017

K. Hemminki, Familial risk and familial survival in prostate cancer, World J Urol, vol.30, issue.2, pp.143-151, 2012.

V. Molinié, M. Sibony, G. Fromont, M. De-fromont, G. Aillet et al., Ann Pathol, vol.28, issue.5, pp.467-73, 2008.

D. F. Gleason, Classification of prostatic carcinomas, Cancer Chemother Rep, vol.50, issue.3, pp.125-133, 1966.

J. I. Epstein, L. Egevad, M. B. Amin, B. Delahunt, J. R. Srigley et al., Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System, The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of, 2001.

F. H. Schröder, J. Hugosson, M. J. Roobol, T. Tammela, M. Zappa et al., Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. The Lancet, vol.384, pp.2027-2062, 2014.

A. Godtman, R. Holmberg, E. Lilja, H. Stranne, J. Hugosson et al., Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial, Eur Urol, vol.68, issue.3, pp.354-60, 2015.

. Ameli and . Guide, Dépistage du cancer de la prostate, 2018.

F. Rozet, C. Hennequin, J. Beauval, P. Beuzeboc, L. Cormier et al., Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer de la prostate, Prog En Urol, vol.27, pp.95-143, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02297771

I. M. Thompson, D. K. Pauler, P. J. Goodman, C. M. Tangen, M. S. Lucia et al., Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ?4.0 ng per Milliliter, N Engl J Med, vol.350, issue.22, pp.2239-2285, 2004.

A. Semjonow, B. Brandt, F. Oberpenning, S. Roth, and L. Hertle, Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values, Prostate Suppl, vol.7, pp.3-16, 1996.

R. Hara, Y. Jo, T. Fujii, N. Kondo, T. Yokoyoma et al., Optimal Approach for Prostate Cancer Detection as Initial Biopsy: Prospective Randomized Study Comparing Transperineal Versus Transrectal Systematic 12-Core Biopsy, Urology, vol.71, issue.2, pp.191-196, 2008.

S. Abuzallouf, I. Dayes, and H. Lukka, BASELINE STAGING OF NEWLY DIAGNOSED PROSTATE CANCER: A SUMMARY OF THE LITERATURE, J Urol, vol.171, issue.6, pp.2122-2129, 2004.

Z. S. Zumsteg, D. E. Spratt, P. I. Zhang, Z. Yamada, Y. Kollmeier et al., A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy, Eur Urol, vol.64, issue.6, pp.895-902, 2013.

A. V. D'amico, R. Whittington, S. B. Malkowicz, K. Cote, M. Loffredo et al., Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer, vol.95, pp.281-287, 2002.

C. Buron, L. Vu, B. Cosset, J. Pommier, P. Peiffert et al., Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study, Int J Radiat Oncol Biol Phys, vol.67, issue.3, pp.812-834, 2007.

M. Bolla, G. Van-tienhoven, W. P. Dubois, J. B. Mirimanoff, R. Storme et al., External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, vol.11, issue.11, pp.1066-73, 2010.

S. A. Boorjian, R. J. Karnes, R. Viterbo, L. J. Rangel, E. J. Bergstralh et al., Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with highrisk prostate cancer, Cancer, vol.117, issue.13, pp.2883-91, 2011.

J. R. Sathya, I. R. Davis, J. A. Julian, Q. Guo, D. Daya et al., Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate, J Clin Oncol, vol.23, issue.6, pp.1192-1201, 2005.

P. J. Hoskin, A. M. Rojas, P. J. Bownes, G. J. Lowe, P. J. Ostler et al., Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer, Radiother Oncol, vol.103, issue.2, pp.217-239, 2012.

W. J. Morris, S. Tyldesley, S. Rodda, R. Halperin, H. Pai et al., Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High-and Intermediate-risk Prostate Cancer, Int J Radiat Oncol, vol.98, issue.2, pp.275-85, 2017.

N. G. Zaorsky, B. J. Davis, P. L. Nguyen, T. N. Showalter, P. J. Hoskin et al., The evolution of brachytherapy for prostate cancer, Nat Rev Urol, vol.14, issue.7, pp.415-454, 2017.

B. J. Davis, E. M. Horwitz, W. R. Lee, J. M. Crook, R. G. Stock et al., American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy, Brachytherapy, vol.11, issue.1, pp.6-19, 2012.

A. Polo, C. Salembier, J. Venselaar, and P. Hoskin, Review of intraoperative imaging and planning techniques in permanent seed prostate brachytherapy, Radiother Oncol, vol.94, issue.1, pp.12-23, 2010.

D. Ash, A. Flynn, J. Battermann, T. De-reijke, P. Lavagnini et al., ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.57, issue.3, pp.315-336, 2000.

T. Shaikh, N. G. Zaorsky, K. Ruth, D. Y. Chen, R. E. Greenberg et al., Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment, Brachytherapy, vol.14, issue.3, pp.316-337, 2015.

P. Pommier, S. Guérif, D. Peiffert, G. Créhange, J. Hannoun-lévi et al., Curiethérapie des cancers de la prostate. Cancer/Radiothérapie, vol.20, pp.210-215, 2016.

J. M. Crook, L. Potters, R. G. Stock, and M. J. Zelefsky, Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk, Brachytherapy, vol.4, issue.3, pp.186-94, 2005.

C. Salembier, P. Lavagnini, P. Nickers, P. Mangili, A. Rijnders et al., Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.83, issue.1, pp.3-10, 2007.

G. S. Merrick, W. M. Butler, K. E. Wallner, J. H. Lief, R. L. Anderson et al., The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction, Int J Radiat Oncol Biol Phys, vol.54, issue.4, pp.1055-62, 2002.

K. A. Hinnen, J. J. Battermann, J. Van-roermund, M. A. Moerland, I. M. Jürgenliemk-schulz et al., Long-Term Biochemical and Survival Outcome of 921 Patients Treated With I-125

, Permanent Prostate Brachytherapy, Int J Radiat Oncol, vol.76, issue.5, pp.1433-1441, 2010.

M. J. Zelefsky, D. A. Kuban, L. B. Levy, L. Potters, D. C. Beyer et al., Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation, Int J Radiat Oncol, vol.67, issue.2, pp.327-360, 2007.

N. N. Stone, L. Potters, B. J. Davis, J. P. Ciezki, M. J. Zelefsky et al., Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes, Int J Radiat Oncol, vol.69, issue.5, pp.1472-1479, 2007.

P. Grimm, I. Billiet, D. Bostwick, A. P. Dicker, S. Frank et al., Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group: CANCER CONTROL RATES: COMPARISON OF TREATMENT OPTIONS, BJU Int, vol.109, pp.22-31, 2012.

A. B. Chen, D. 'amico, A. V. Neville, B. A. Earle, and C. C. , Patient and Treatment Factors Associated With Complications After Prostate Brachytherapy, J Clin Oncol, vol.24, issue.33, pp.5298-304, 2006.

J. M. Crook, A. Gomez-iturriaga, K. Wallace, C. Ma, S. Fung et al., Comparison of HealthRelated Quality of Life 5 Years After SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial, J Clin Oncol, vol.29, issue.4, pp.362-370, 2011.

D. Ash, B. Al-qaisieh, D. Bottomley, B. Carey, and J. Joseph, The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer, Radiother Oncol, vol.79, issue.2, pp.185-194, 2006.

R. G. Stock, N. N. Stone, A. Tabert, C. Iannuzzi, and J. K. Dewyngaert, A dose-response study for I-125 prostate implants, Int J Radiat Oncol Biol Phys, vol.41, issue.1, pp.101-109, 1998.

J. L. Mohler, A. J. Armstrong, R. R. Bahnson, D. 'amico, A. V. Davis et al., Prostate Cancer, Version 1.2016. J Natl Compr Cancer Netw JNCCN, vol.14, pp.19-30, 2016.

M. Roach, G. Hanks, H. Thames, P. Schellhammer, W. U. Shipley et al., Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol, vol.65, issue.4, pp.965-74, 2006.

P. D. Grimm, J. C. Blasko, J. E. Sylvester, R. M. Meier, and W. Cavanagh, 10-year biochemical (prostatespecific antigen) control of prostate cancer with (125)I brachytherapy, Int J Radiat Oncol Biol Phys, vol.51, issue.1, pp.31-40, 2001.

C. M. Iannuzzi, R. G. Stock, and N. N. Stone, PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer, Radiat Oncol Investig, vol.7, issue.1, pp.30-35, 1999.

M. Caloglu and J. Ciezki, Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon, Urology, vol.74, issue.6, pp.1183-90, 2009.

K. E. Wallner, J. Blasko, and M. G. Dattoli, Prostate brachytherapy made complicated

S. D. Mcgrath, J. V. Antonucci, D. L. Fitch, M. Ghilezan, G. S. Gustafson et al., PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation, Brachytherapy, vol.9, issue.2, pp.137-181, 2010.

A. Toledano, L. Chauveinc, T. Flam, N. Thiounn, S. Solignac et al., PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure, Cancer Radiother J Soc Francaise Radiother Oncol, vol.11, issue.3, pp.105-115, 2007.

C. Hackett, S. Ghosh, R. Sloboda, K. Martell, L. Lan et al., Distinguishing prostatespecific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy, J Contemp Brachytherapy, vol.6, issue.3, pp.247-53, 2014.

G. S. Merrick, W. M. Butler, K. E. Wallner, R. W. Galbreath, and R. L. Anderson, Prostate-specific antigen spikes after permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys, vol.54, issue.2, pp.450-456, 2002.

R. G. Stock, N. N. Stone, and J. A. Cesaretti, Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications, Int J Radiat Oncol Biol Phys, vol.56, issue.2, pp.448-53, 2003.

C. Patel, M. A. Elshaikh, K. Angermeier, J. Ulchaker, E. A. Klein et al., PSA bounce predicts early success in patients with permanent iodine-125 prostate implant, Urology, vol.63, issue.1, pp.110-113, 2004.

W. Cavanagh, J. C. Blasko, P. D. Grimm, and J. E. Sylvester, Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer, Semin Urol Oncol, vol.18, issue.2, pp.160-165, 2000.

F. A. Critz, W. H. Williams, J. B. Benton, A. K. Levinson, C. T. Holladay et al., Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer, J Urol, vol.163, issue.4, pp.1085-1094, 2000.

C. J. Rosser, D. A. Kuban, L. B. Levy, R. Chichakli, A. Pollack et al., Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer, J Urol, vol.168, issue.5, pp.2001-2006, 2002.

A. L. Hanlon, W. H. Pinover, E. M. Horwitz, and G. E. Hanks, Patterns and fate of PSA bouncing following 3D-CRT, Int J Radiat Oncol Biol Phys, vol.50, issue.4, pp.845-854, 2001.

P. K. Agarwal, N. Sadetsky, B. R. Konety, M. I. Resnick, and P. R. Carroll, and the Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) Investigators. Treatment failure after primary and salvage therapy for prostate cancer: Likelihood, patterns of care, and outcomes. Cancer, vol.112, pp.307-321, 2008.

C. Neppl-huber, M. Zappa, J. W. Coebergh, E. Rapiti, J. Rachtan et al., Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths, Ann Oncol Off J Eur Soc Med Oncol, vol.23, issue.5, pp.1325-1359, 2012.

L. Quero, L. Vercellino, E. De-kerviler, P. Mongiat-artus, S. Culine et al., 18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer, Clin Nucl Med, vol.40, issue.11, pp.492-497, 2015.

J. J. Coen, A. L. Zietman, H. Thakral, and W. U. Shipley, Radical Radiation for Localized Prostate Cancer: Local Persistence of Disease Results in a Late Wave of Metastases, J Clin Oncol, vol.20, issue.15, pp.3199-205, 2002.

C. Hennequin, J. Hannoun-lévi, and F. Rozet, Management of local relapse after prostate cancer radiotherapy: Surgery or radiotherapy? Cancer/Radiothérapie, vol.21, pp.433-439, 2017.

C. J. Kane, C. L. Amling, P. Johnstone, N. Pak, R. S. Lance et al., Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy, Urology, vol.61, issue.3, pp.607-618, 2003.

J. Kurhanewicz, M. G. Swanson, S. J. Nelson, and D. B. Vigneron, Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer, J Magn Reson Imaging JMRI, vol.16, issue.4, pp.451-63, 2002.

B. G. Muller, J. J. Fütterer, R. T. Gupta, A. Katz, A. Kirkham et al., The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel, BJU Int, vol.113, issue.2, pp.218-245, 2014.

V. A. Morgan, S. F. Riches, S. Giles, D. Dearnaley, and N. M. Desouza, Diffusion-Weighted MRI for Locally Recurrent Prostate Cancer After External Beam Radiotherapy, Am J Roentgenol, vol.198, issue.3, pp.596-602, 2012.

H. A. Vargas, C. Wassberg, O. Akin, and H. Hricak, MR imaging of treated prostate cancer, Radiology, vol.262, issue.1, pp.26-42, 2012.

L. M. Wu, J. Xu, H. Y. Gu, J. Hua, J. Zhu et al., Role of Magnetic Resonance Imaging in the Detection of Local Prostate Cancer Recurrence after External Beam Radiotherapy and Radical Prostatectomy, Clin Oncol, vol.25, issue.4, pp.252-64, 2013.

F. V. Coakley, H. S. Teh, A. Qayyum, M. G. Swanson, Y. Lu et al., Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience, Radiology, vol.233, issue.2, pp.441-449, 2004.

L. Dias, J. Lucas, R. , M. Pina, J. João et al., Post-treated prostate cancer: normal findings and signs of local relapse on multiparametric magnetic resonance imaging, Abdom Imaging, vol.40, issue.7, pp.2814-2852, 2015.

A. Kirilova, A. Damyanovich, J. Crook, J. Jezioranski, K. Wallace et al., 3D MR-Spectroscopic Imaging Assessment of Metabolic Activity in the Prostate During the PSA "Bounce" Following 125Iodine Brachytherapy, Int J Radiat Oncol, vol.79, issue.2, pp.371-379, 2011.

N. Oyama, H. Akino, Y. Suzuki, H. Kanamaru, N. Sadato et al., The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer, Jpn J Clin Oncol, vol.29, issue.12, pp.623-632, 1999.

T. R. Degrado, R. E. Coleman, S. Wang, S. W. Baldwin, M. D. Orr et al., Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer, Cancer Res, vol.61, issue.1, pp.110-117, 2001.

M. H. Umbehr, M. Müntener, T. Hany, T. Sulser, and L. M. Bachmann, The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis, Eur Urol, vol.64, issue.1, pp.106-123, 2013.

G. Treglia, L. Ceriani, R. Sadeghi, G. Giovacchini, and L. Giovanella, Relationship between prostatespecific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis, Clin Chem Lab Med, 2014.

F. J. Bianco, P. T. Scardino, A. J. Stephenson, C. J. Diblasio, P. A. Fearn et al., Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy, Int J Radiat Oncol, vol.62, issue.2, pp.448-53, 2005.

H. Tran, J. Kwok, T. Pickles, S. Tyldesley, and P. C. Black, Underutilization of local salvage therapy after radiation therapy for prostate cancer, Urol Oncol, vol.32, issue.5, pp.701-707, 2014.

H. Ahmadi, S. Daneshmand, R. Van-den-bergh, N. J. Van-casteren, T. Van-den-broeck et al., Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review, Eur Urol, vol.111, issue.4, pp.802-822, 2013.

S. Punnen, M. R. Cooperberg, D. 'amico, A. V. Karakiewicz, P. I. Moul et al., Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature, Eur Urol, vol.64, issue.6, pp.905-920, 2013.

E. Kaljouw, B. R. Pieters, G. Kovács, and P. J. Hoskin, A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study, Radiother Oncol, vol.118, issue.1, pp.122-152, 2016.

S. J. Ramey and D. T. Marshall, Re-irradiation for salvage of prostate cancer failures after primary radiotherapy, World J Urol, vol.31, issue.6, pp.1339-1384, 2013.

J. Cosset and G. Créhange, Curiethérapie prostatique de rattrapage : solution pour les rechutes localisées après irradiation ? Cancer/Radiothérapie, vol.21, p.821, 2017.

C. C. Hsu, H. Hsu, B. Pickett, G. Crehange, I. Hsu et al., Feasibility of MR Imaging/MR Spectroscopy-Planned Focal Partial Salvage Permanent Prostate Implant (PPI) for Localized Recurrence After Initial PPI for Prostate Cancer, Int J Radiat Oncol, vol.85, issue.2, pp.370-377, 2013.

D. B. Fuller, J. Wurzer, R. Shirazi, S. S. Bridge, J. Law et al., High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment, Pract Radiat Oncol, vol.5, issue.6, pp.615-623, 2015.

E. Kaljouw, B. R. Pieters, G. Kovács, and P. J. Hoskin, Radiother Oncol, vol.118, issue.1, pp.122-152, 2016.

V. Mouraviev, P. E. Spiess, and J. S. Jones, Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy, Eur Urol, vol.61, issue.6, pp.1204-1215, 2012.

U. Ahmed, H. Cathcart, P. Chalasani, V. Williams, A. Mccartan et al., Wholegland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy, Cancer, vol.118, issue.12, pp.3071-3079, 2012.

O. Rouvière, Imaging techniques for local recurrence of prostate cancer: For whom, why and how? Diagn Interv Imaging, vol.93, pp.279-90, 2012.

L. Thomas, A. Chemin, N. Leduc, S. Belhomme, E. Rich et al., Manual vs. automated implantation of seeds in prostate brachytherapy: Oncologic results from a singlecenter study, Brachytherapy, vol.17, issue.1, pp.214-234, 2018.

C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson et al., Natural history of progression after PSA elevation following radical prostatectomy, JAMA, vol.281, issue.17, pp.1591-1598, 1999.

E. R. Delong, D. M. Delong, and D. L. Clarke-pearson, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, vol.44, issue.3, pp.837-882, 1988.

H. B. Mann and D. R. Whitney, On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other, Ann Math Stat, vol.18, issue.1, pp.50-60, 1947.

I. T. Jolliffe, Principal Component Analysis, Second Edition, 2002.

M. H. Umbehr, M. Müntener, T. Hany, T. Sulser, and L. M. Bachmann, The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis, Eur Urol, vol.64, issue.1, pp.106-123, 2013.

S. Fanti, S. Minozzi, P. Castellucci, S. Balduzzi, K. Herrmann et al., PET/CT with (11)Ccholine for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data, Eur J Nucl Med Mol Imaging, vol.43, issue.1, pp.55-69, 2016.

M. Eiber, T. Maurer, M. Souvatzoglou, A. J. Beer, A. Ruffani et al., Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy, J Nucl Med, vol.56, issue.5, pp.668-74, 2015.

A. Afshar-oromieh, C. M. Zechmann, A. Malcher, M. Eder, M. Eisenhut et al., Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, vol.41, issue.1, pp.11-20, 2014.

I. Einspieler, I. Rauscher, C. Düwel, M. Krönke, C. Rischpler et al., Detection Efficacy of Hybrid 68 Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria, J Nucl Med, vol.58, issue.7, pp.1081-1088, 2017.

F. K. Mostofi, I. A. Sesterhenn, and C. J. Davis, A pathologist's view of prostatic carcinoma, Cancer, vol.71, issue.3, pp.906-938, 1993.

J. Crook, S. Malone, G. Perry, Y. Bahadur, S. Robertson et al., Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients, Int J Radiat Oncol Biol Phys, vol.48, issue.2, pp.355-67, 2000.

G. Crehange, D. Krishnamurthy, J. A. Cunha, B. Pickett, J. Kurhanewicz et al., Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy, Radiother Oncol, vol.109, issue.2, pp.246-50, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00966728

G. S. Merrick, W. M. Butler, P. Grimm, M. Morris, J. H. Lief et al., Multisector prostate dosimetric quality: Analysis of a large community database, Brachytherapy, vol.13, issue.2, pp.146-51, 2014.

M. Orré, T. Piéchaud, P. Sargos, P. Richaud, G. Roubaud et al., Oncological and functional results of robotic salvage radical prostatectomy after permanent brachytherapy implants. Cancer/Radiothérapie, vol.21, pp.119-142, 2017.

G. Créhange, M. Roach, M. É. Cormier, L. Peiffert, D. Cochet et al., Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how? Cancer/Radiothérapie, vol.18, pp.524-558, 2014.

A. V. D'amico, Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer, JAMA, vol.280, issue.11, p.969, 1998.

I. Spadinger, W. J. Morris, M. Keyes, M. Liu, R. Shaffer et al., Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapy, Brachytherapy, vol.10, issue.2, pp.87-97, 2011.

S. Sidhu, W. J. Morris, I. Spadinger, M. Keyes, M. Hilts et al., Prostate brachytherapy postimplant dosimetry: a comparison of prostate quadrants, Int J Radiat Oncol Biol Phys, vol.52, issue.2, pp.544-52, 2002.

M. Roach, J. Kurhanewicz, and P. Carroll, Spectroscopy in prostate cancer: hope or hype? Oncol Williston Park N, vol.15, pp.1415-1416, 1418.

C. R. Pound, Natural History of Progression After PSA Elevation Following Radical Prostatectomy, JAMA, vol.281, issue.17, p.1591, 1999.

L. E. Serment-d'hippocrate,

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs. Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonorée et méprisée si j'y manque